Morgan Stanley expects Novo Nordisk Alzheimer trial to fail as it slashes rating
Short excerpt below. Click through to read at the original source.
Morgan Stanley analysts say a trial to test whether Novo Nordisk’s blockbuster weight-loss drug also will work against Alzheimer’s is likely to fail, as it set the most pessimistic target price forecast of any Wall Street bank on the Danish drugmaker.